(Amoxicillin sodium + clavulanate potassium) is a Small Molecule owned by GSK, and is involved in 38 clinical trials, of which 36 were completed, and 2 are planned.

Amoxicillin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis.

Clavulanate potassium competitively and irreversibly inhibits a wide variety of beta-lactamases, commonly found in microorganisms resistant to penicillins and cephalosporins. Binding and irreversibly inhibiting the beta-lactamase results in a restauration of the antimicrobial activity of beta-lactam antibiotics against lactamase-secreting-resistant bacteria. By inactivating beta-lactamase (the bacterial resistance protein), the accompanying penicillin/cephalosporin drugs may be made more potent as well.

The revenue for (Amoxicillin sodium + clavulanate potassium) is expected to reach a total of $10.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Amoxicillin sodium + clavulanate potassium) NPV Report.

(Amoxicillin sodium + clavulanate potassium) is currently owned by GSK.

(Amoxicillin sodium + clavulanate potassium) Overview

Amoxicillin and Clavulanate potassium (Augmentin, Augmentin Trio forte, Clavulin, Augmentin Duo, Augmentin ES, Clavamox, Augmentin Forte, Augmentin Duo Forte, Agumentin P, Augmentin BD, Augmentin BD SF, Augmentin BD S, Augmentin ES) is a fixed dose combination drug, acts as an antibacterial agent. It is formulated as tablets, film coated tablets, chewable tablets, granules, powder for suspension and powder for solution for oral route of administration and powder for solution for intravenous route of administration. It is indicated for the treatment of lower respiratory tract infections which are caused by beta-lactamase-producing strains of H. influenzae and M. Catarrhalis, otitis media caused by beta-lactamase-producing strains of H. influenzae and M. Catarrhalis. It is further used for the treatment of sinusitis caused by beta-lactamase-producing strains of H. influenzae and M. Catarrhalis, skin and skin structure infections caused by beta-lactamase-producing strains of S. aureus, E. coli, and Klebsiella species, and urinary tract infections caused by beta-lactamase-producing strains of E. coli, Klebsiella spp., and Enterobacter spp.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – (Amoxicillin sodium + clavulanate potassium)

Report Segments
  • Innovator (NME)
Drug Name
  • (Amoxicillin sodium + clavulanate potassium)
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Ear Nose Throat Disorders
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
  • Mouth and Dental Disorders
  • Musculoskeletal Disorders
  • Respiratory
  • Women’s Health
Key Companies
  • Sponsor Company: GSK
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.